23 June 2016 - The Transparency Commission will consider the reimbursement of migalastat hydrochloride (Galafold), lignocaine hydrochloride with phenylephrine hydrochloride and tropicamide (Mydrane), autologous corneal epithelial cells including stem cells (Holocar) and metyrapone (Metyrapone HRA).

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-06/ordre_du_jour_ct_29062016.pdf [French]